|Generic Medicine - WHO - GMP Certified|
|Cefazoline for Injection|
Vildagliptin (previously LAF237, trade names Galvus, Zomelis,) is an oral anti-hyperglycemic agent (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. Vildagliptin inhibits the inactivation of GLP-1 and GIP by DPP-4, allowing GLP-1 and GIP to potentiate the secretion of insulin in the beta cells and suppress glucagon release by the alpha cells of the islets of Langerhans in the pancreas.
Our packaging materials can retain the products' quality and newness even under extreme shipping and handling conditions. Our packaging provides optimum physical protection. We keep the finished assortment of products in highly developed and spacious space. This helps us in keeping products secure and sorted.
Vildagliptin has been shown to reduce hyperglycemia in type 2 diabetes mellitus.